Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Public ClinicalTrials.gov record NCT04952610. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Extension Study of Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any significant safety issues during participation period in a previous clinical trial of etripamil NS, as per Investigator's assessment , are excluded. This study will be conducted by Investigators who previously participated in a Milestone Pharmaceuticals clinical trial and are trained on the use of etripamil NS.
Study identification
- NCT ID
- NCT04952610
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2021 (Actual)
- Primary completion
- Apr 10, 2026 (Actual)
- Completion
- Apr 10, 2026 (Actual)
- Last update posted
- May 15, 2026
2021 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site # 0160 | Little Rock | Arkansas | 72205 | — |
| Site # 1023 | Vista | California | 92083 | — |
| Site # 1083 | West Hills | California | 91307 | — |
| Site # 0102 | Atlanta | Georgia | 30309 | — |
| Site # 0137 | Macon | Georgia | 31201 | — |
| Site # 1115 | Coeur d'Alene | Idaho | 83814 | — |
| Site # 0149 | Fort Wayne | Indiana | 46845 | — |
| Site # 1025 | West Des Moines | Iowa | 50266 | — |
| Site # 1007 | Salisbury | Maryland | 21801 | — |
| Site # 0166 | Lansing | Michigan | 48912 | — |
| Site # 0114 | New York | New York | 10065 | — |
| Site # 1024 | Canton | Ohio | 44710 | — |
| Site # 0110 | Toledo | Ohio | 43606- | — |
| Site # 1123 | Corvallis | Oregon | 97330 | — |
| Site # 0105 | Yardley | Pennsylvania | 19067 | — |
| Site # 0122 | Rapid City | South Dakota | 57701 | — |
| Site # 1047 | Austin | Texas | 78723 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04952610, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04952610 live on ClinicalTrials.gov.